Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217525 | 0.85 | CA12 (0.33) | CA14CA12CA1CA2MMP1 | |
| SCHEMBL5126842 | 0.74 | HDAC1 (0.37) | TAS1R3TAS1R1CA12CA2MMP2 | |
| SCHEMBL4737941 | 0.67 | TAS1R3 (0.39) | TAS1R3TAS1R1TAS1R2CA12CA1 | |
| SCHEMBL3219197 | 0.67 | CA12 (0.44) | CA14CA12CA2CA9 | |
| SCHEMBL26133308 | 0.66 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2CA14CA12 | |
| SCHEMBL13888611 | 0.66 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2CA14CA12 | |
| SCHEMBL17506705 | 0.66 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2CA14CA12 | |
| SCHEMBL10782278 | 0.66 | — | — | |
| SCHEMBL3204791 | 0.66 | SMN1; SMN2 (0.46) | CA14CA12CA1CA2CA9 | |
| SCHEMBL7367893 | 0.64 | TAS1R3 (0.46) | TAS1R3TAS1R1TAS1R2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | TAS1R3 4562/4885TAS1R1 4426/4885TAS1R2 4553/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | TAS1R3 4159/4885TAS1R1 3700/4885TAS1R2 3938/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | TAS1R3 4562/4885TAS1R1 4426/4885TAS1R2 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.